Avita has initiated a trial in the UK to evaluate the potential of its ReGenerCell technology to treat diabetic foot ulcers, a skin wound that can be very hard to treat.
With offices in the UK and originally from Australia, Avita Medical is developing products in tissue engineering and regenerative medicine.
Its technology utilises the patient’s own skin and the regenerative capability of the human body to treat a wide range of wounds, scars and skin defects.
The ReGenerCell device enables medical professionals to use a small sample of the patient’s skin to create an autologous suspension, containing multiple types of cells and wound-healing factors.
This suspension is then sprayed or dripped in the wound’s area.
Now, Avita is tackling a new condition, diabetic foot ulcer. It has enrolled the first patient at the Manchester Royal Infirmary for a 26-week trial. The study will have up to 24 patients, all still undergoing standard treatments –